採用
Celestial AI

Celestial AI
AI accelerator chips
Machine Learning
Hardware Acceleration
Distributed Systems
Photonic Computing
募集中のポジション
0件のポジション
現在募集中のポジションはありません
製品・サービス
PH
Photonic Fabric
Hardware Platform
OR
Orion Photonic Accelerator
AI Accelerator
PH
Photonic Memory Interface
Memory Technology
OP
Optical I/O Technology
Interconnect Technology
AI
AI Development Platform
Software Platform
CU
Custom Silicon Solutions
Custom Hardware
類似企業

Fal
growth
Media-generating AI models
Valuation 4.5B

Unconventional AI
growth
AI computing infrastructure
1-50
Valuation 4.5B

Eve
growth
AI tools for law firms
Hillsborough, North Carolina
1,001-5,000
Valuation 1.0B

PixVerse
growth
AI video generation
51-200
Valuation 1.0B
Cambricon
late
AI chip designer
北京市, 中国
1,001-5,000
Valuation 72.5B

Legora
growth
AI legal assistant
Valuation 5.6B
ニュース&話題
All
X
News
HN
YouTube
Open-source isolated runtime for AI agents
HN
·
3日前
·
2
·
3
Stifel Raises Marvell’s Target to $140: Is This AI Chip Dark Horse Ready to Break Out? - 24/7 Wall St.
24/7 Wall St.
News
·
5日前
Show HN: SmolVM – open-source sandbox for coding and computer-use agents
SmolVM is an open-source local sandbox for AI agents on macOS and Linux.<p>I started building it because agent workflows need more than isolated code execution. They need a reusable environment: write files in one step, come back later, snapshot state, pause/resume, and increasingly interact with browsers or full desktop environments.<p>Right now SmolVM is a Python SDK and CLI focused on local developer experience.<p>Current features include: - local sandbox environments - macOS and Linux s
HN
·
1週間前
·
8
·
3
Firms act on Marvell Technology’s USD3.25bn Celestial AI buy - Law.asia
Law.asia
google-news
·
3週間前
My portfolio and short thesis for each stock
Please let me know what you think of this portfolio any critique or advice would be helpful TSM 15% - (Avg entry - 292$) The only manufacturer of the world's most advanced chips. Every AI accelerator on the planet runs through TSMC's fabs and no competitor is within a decade of catching up. LLY 12% - (Avg entry - $850) Owns the defining drug franchise of this generation with tirzepatide and orforglipron targeting obesity and diabetes at scale. Yes, overpriced but price falling to low 900 makes
·
1ヶ月前
·
35
·
29
もっと見る (残り15件)
総閲覧数
0
応募クリック数
0
模擬応募者数
0
スクラップ
0
給与レンジ
6件のデータ
Senior/L5
Senior/L5
1件のレポート
$240,531
年収総額
基本給
$185,024
ストック
-
$240,531
$240,531
連絡先・所在地